Description

Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide acetate inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide acetate can be used for the research of ulcerative colitis[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)—-C59H105N17O11.C2H4O2—-[1]Arthur Kaser, et al. Novel therapeutic targets in the treatment of IBD. Kaser, Arthur; Tilg, Herbert (2008). Expert Opinion on Therapeutic Targets, 12(5), 553–563.|[2]Jingsong Zhao, et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004 Apr 15;10(8):2851-9.–501019-16-5–1288.62–98.55–N=C(N)NCCC[C@@H](N)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCC)C(NCC(N[C@@H](C(N)=O)CC1=CC=C(O)C=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O–Cancer–10 mM in DMSO–IFNAR;Reactive Oxygen Species;TNF Receptor—-Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB–Peptides